Summary
A bioRxiv preprint reports that the RIG-I agonist SLR14 reduced infection or viral replication in human-derived cells and improved outcomes in infected mice. The findings come from cell and animal experiments, not human treatment studies.
A bioRxiv preprint reports that SLR14, a stem-loop RNA that activates the immune sensor RIG-I, reduced infection or viral replication across cell models of five highly pathogenic RNA viruses. In mice, the researchers also found protection against lethal Rift Valley fever virus (RVFV) infection and improved survival after Ebola virus infection. The findings are preclinical: they come from cells and animals, not people receiving treatment.
What the experiments found
The researchers tested SLR14 against Ebola, Marburg and Sudan viruses in human primary monocyte-derived macrophages, and against Nipah virus in induced pluripotent stem cell-derived endothelial cells. The preprint reports marked reductions in infection for the three viruses tested in macrophages and reduced Nipah virus replication in the endothelial cells. It reports activity when SLR14 was given before infection and when given after infection.
In mice, a single SLR14 dose protected against lethal RVFV infection when administered before infection. The treatment retained significant efficacy when given as late as two days after infection. In a separate Ebola mouse model, therapeutic SLR14 administration improved survival. The abstract does not give numerical survival estimates or describe the dose regimens.
RIG-I is part of the innate immune system, which can detect viral RNA and initiate antiviral signalling. Activating a host defence pathway, rather than targeting a feature unique to one virus, offers a possible route to antiviral activity across different viruses. That breadth is the central finding reported here; it does not mean that every RNA virus will respond to SLR14.
The immune response is part of the finding
The authors compared immune activity in human macrophages during Ebola infection with the response after SLR14 treatment. The two conditions activated some overlapping innate immune pathways, but the preprint describes different outcomes: infection produced a response that was not protective, while SLR14 produced a stronger, regulated signature involving interferon-stimulated and inflammatory genes. The authors also report that SLR14 avoided prolonged upregulation of interferon genes.
This suggests that the treatment’s effects may depend not simply on triggering an immune response, but on the pattern and timing of that response. The reported immune signature helps explain why the authors consider SLR14 a host-directed antiviral candidate.
What the results mean
The combination of cell experiments and mouse infection models supports further study of SLR14 as a potential countermeasure against several dangerous viruses. The post-infection results are especially relevant to treatment, since they show activity in the models after infection had begun. The strongest translational limit is that these are preclinical findings: the preprint reports no human treatment outcomes. It is posted on bioRxiv as a preprint.